A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost

Journal of Acquired Immune Deficiency Syndromes

Volumn 46, Issue 1, 2007, Pages 48-55

  Thongcharoen, Prasert ^a   Suriyanon, Vinai ^b   Paris, Robert M ^c   Khamboonruang, Chirasak ^b   De Souza, Mark S ^c   Ratto Kim, Silvia ^c   Karnasuta, Chitraporn ^c   Polonis, Victoria R ^d   Baglyos, Lynn ^e   Habib, Raphaelle El ^e   Gurunathan, Sanjay ^e   Barnett, Susan ^f   Brown, Arthur E ^g   Birx, Deborah L ^h   McNeil, John G ⁱ   Kim, Jerome H ^c  

^a MAHIDOL UNIVERSITY   (Thailand)

^b CHIANG MAI UNIVERSITY   (Thailand)

^c ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^d HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^e SANOFI PASTEUR   (France)

^f Novartis Vaccines and Diagnostics Inc   (United States)

^g US Army Medical Materiel Development Activity   (United States)

^h CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

ⁱ PATH Malaria Vaccine Initiative   (United States)

Author keywords

CRF01_AE; HIV 1; Phase 1 2; Subtype E; Thailand; Vaccine

Indexed keywords

ADJUVANT; GAG PROTEIN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 160; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; NEUTRALIZING ANTIBODY; PLACEBO; POLY[DI(CARBOXYLATEPHENOXY)]PHOSPHAZENE; UNCLASSIFIED DRUG; VIRUS VECTOR;

ADULT; ANIMAL CELL; ANTIBODY RESPONSE; ARTICLE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE WARMTH; LACERATION; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MYALGIA; NONHUMAN; NUCLEOTIDE SEQUENCE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; STATISTICAL SIGNIFICANCE; UPPER RESPIRATORY TRACT INFECTION;

ADULT; AIDS VACCINES; CELL PROLIFERATION; DOUBLE-BLIND METHOD; FEMALE; HIV ANTIBODIES; HIV ANTIGENS; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP160; HIV INFECTIONS; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; PROTEIN BINDING; VACCINATION;

EID: 34848908400     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181354bd7     Document Type: Article

References (21)

1. Ruxrungtham K, Brown T, Phanuphak P. HIV/AIDS in Asia. Lancet. 2004;364:69-82.
2. Tovanabutra S, Beyrer C, Sakkhachornphop S, et al. The changing molecular epidemiology of HIV type 1 among northern Thai drug users, 1999 to 2002. AIDS Res Hum Retroviruses. 2004;20:465-475.
3. Viputtijul K, de Souza M, Trichavaroj R, et al. Heterosexually acquired CRF01_AE/B recombinant HIV type 1 found in Thailand. AIDS Res Hum Retroviruses. 2002;18:1235-1237.
4. Nitayaphan S, Pitisuttithum P, Karnasuta C, et al. Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J Infect Dis. 2004;190:702-706.
5. Pitisuttithum P, Nitayaphan S, Thongcharoen P, et al. Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults. J Infect Dis. 2003;188:219-227.
6. Evans TG, Keefer MC, Weinhold KJ, et al. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis. 1999;180:290-298.
7. Nitayaphan S, Khamboonruang C, Sirisophana N, et al. A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative Thais. AFRIMS-RIHES Vaccine Evaluation Group. Armed Forces Research Institute of Medical Sciences and the Research Institute for Health Sciences. Vaccine. 2000;18:1448-1455.
8. VanCott TC, Mascola JR, Kaminski RW, et al. Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160. J Virol. 1997;71:4319-4330.
9. Paris R, Bejrachandra S, Karnasuta C, et al. HLA class I serotypes and cytotoxic T-lymphocyte responses among human immunodeficiency virus-1-uninfected Thai volunteers immunized with ALVAC-HIV in combination with monomeric gp120 or oligomeric gp160 protein boosting. Tissue Antigens. 2004;64:251-256.
10. Rerks-Ngarm S, Brown AE, Khamboonruang C, et al. HIV/AIDS preventive vaccine 'prime-boost' phase III trial: foundations and initial lessons learned from Thailand. AIDS. 2006;20:1471-1479.
11. de Bruyn G, Rossini AJ, Chiu YL, et al. Safety profile of recombinant canarypox HIV vaccines. Vaccine. 2004;22:704-713.
12. Ackers ML, Parekh B, Evans TG, et al. Human immunodeficiency virus (HIV) seropositivity among uninfected HIV vaccine recipients. J Infect Dis. 2003;187:879-886.
13. Gorse GJ, Patel GB, Mandava MD, et al. Cytokine responses to human immunodeficiency virus type 1 (HIV-1) induced by immunization with live recombinant canarypox virus vaccine expressing HIV-1 genes boosted by HIV-1 (SF-2) recombinant GP120. Vaccine. 2001;19:1806-1819.
14. Gorse GJ, Patel GB, Belshe RB. HIV type 1 vaccine-induced T cell memory and cytotoxic T lymphocyte responses in HIV type 1-uninfected volunteers. AIDS Res Hum Retroviruses. 2001;17:1175-1189.
15. Franchini G, Gurunathan S, Baglyos L, et al. Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors. Expert Rev Vaccines. 2004;3(Suppl):S75-S88.
16. Gupta K, Hudgens M, Corey L, et al. Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A. J Acquir Immune Defic Syndr. 2002;29:254-261.
17. Belshe RB, Stevens C, Gorse GJ, et al. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. J Infect Dis. 2001;183:1343-1352.
18. Cao H, Kaleebu P, Hom D, et al. Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study. J Infect Dis. 2003;187:887-895.
19. Russell ND, Graham BS, Keefer MC, et al. Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. J Acquir Immune Defic Syndr. 2007;44:203-212.
20. Hudgens MG. Estimating cumulative probabilities from incomplete longitudinal binary responses with application to HIV vaccine trials. Stat Med. 2003;22:463-479.
21. Fouts TR, Binley JM, Trkola A, et al. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex. J Virol. 1997;71:2779-2785.